ALK (Anaplastic lymphoma kinase)

P2, N=180, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=600 --> 180 | Unknown status --> Terminated; study design, change of standard of care, enrollment difficulties

P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting

As targeted therapies continue to expand across disease stages and treatment lines, CV toxicity is expected to play an increasingly important role in therapeutic decision-making. Integrating CV considerations into oncologic care is therefore essential to preserve treatment continuity, optimize long-term outcomes, and maximize the benefits of modern targeted therapies in NSCLC.

The Pan Lung Cancer PCR Panel was highly concordant with other assays. The panel can be performed in local laboratories with a rapid turnaround time and represents an attractive alternative to next-generation sequencing for patients with lung cancer.

Concurrent targeting of PI3K and IR/IGF-1R signaling effectively overcomes adaptive resistance in PIK3CA-mutant NSCLC, supporting the rationale for further clinical evaluation of this combined therapeutic strategy.

A series of derivatives (D1-D15) was designed and synthesized by incorporating a hydrazone unit into the TAE-226 scaffold...Mechanistically, compound D12 effectively suppressed FAK phosphorylation and downstream MAPK/ERK and AKT/mTOR signaling, leading to inhibition of colony formation, migration, cell cycle progression, and induction of apoptosis. Compound D12 is a novel FAK inhibitor with improved selectivity and potent antitumor activity, representing a promising lead candidate for cancer therapy.

Notably, ALK protein positivity and gene copy number gain were associated with poorer survival outcomes, including 5-year overall survival (OS) and 10-year recurrence-free survival (RFS). Our findings highlight the importance of ALK as a potential therapeutic target in TNBC, emphasizing the need for further investigation into its clinical significance.

P1/2, N=12, Completed, CRISPR Therapeutics | Recruiting --> Completed | N=290 --> 12 | Trial completion date: Nov 2030 --> Mar 2026 | Trial primary completion date: May 2030 --> Mar 2026

P=N/A, N=240, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Reviewing automatically collected data was 5.8 times faster compared with manual collection. Our solution demonstrates robust performance for extracting temporally structured tumor outcomes from EMRs and supports the reconstruction of real-world endpoints in oncology.

After about 20 years of exciting improvements in treatment efficacy outcomes of advanced epidermal growth factor receptor (EGFR) mutant and anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC), also combined with a progressively better safety profile, from chemotherapy to new generation tyrosine kinase inhibitors (TKIs) (osimertinib, alectinib, brigatinib), the recent MARIPOSA and CROWN trials have changed this trend. The story would be easy and totally positive if these two innovative, amazing treatments were not associated with new peculiar features in safety profiles that must be discussed with patients, because they potentially affect their quality of life. When treating these patient populations, the peculiar safety profiles of amivantamab plu lazertinib and lorlatinib require a well-structured shared decision making, "where and when", both the high probability of a longer survival and the risk of worse quality of life must be well announced and explained to our patients before the shared final treatment choice.